{"entity":{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","aka":[],"tldr":"Moffitt is Florida's cancer centre and the leading US site for TIL therapy and evolutionary ('adaptive') therapy research.","summary":"Moffitt Cancer Center in Tampa is Florida's NCI comprehensive cancer centre and the leading US site for tumour-infiltrating lymphocyte therapy and for evolutionary, or adaptive, therapy research. It ran the pivotal lifileucel trials under Amod A. Sarnaik, reported in C-144-01, hosts Robert A. Gatenby's adaptive therapy programme, and runs the ORIEN data network and a broad immuno-oncology effort, with Frederick L. Locke, Eric B. Haura, Christine H. Chung and Shari Pilon-Thomas among its people. OnCo links it to melanoma and lifileucel, to the ZUMA-1 and ZUMA-7 CAR-T papers, and to ideas on dose-holiday platform trials, evolutionary tumour boards and switching drugs at maximum response. Acquired resistance and tumour heterogeneity are the bottlenecks its adaptive therapy work attacks. Its TIL and adaptive therapy programmes are the reasons to read on.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/H._Lee_Moffitt_Cancer_Center_%26_Research_Institute","links":[{"label":"Official website","url":"https://www.moffitt.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":["lifileucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["robert-gatenby","eric-haura","hatem-soliman","christine-chung","shari-pilon-thomas","jonathan-strosberg","amod-sarnaik","frederick-locke","patrick-hwu"],"bottlenecks":[],"keyPapers":[],"journals":["cancer-control"],"dependsOn":[],"notes":[],"city":"Tampa, FL","country":"US","lat":28.066,"lng":-82.42,"institutionType":"cancer-center","website":"https://www.moffitt.org","nci":"comprehensive","programs":["TIL therapy","Adaptive therapy","Immuno-oncology"]},"route":"/institutions/moffitt/","neighbours":{"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"drug":[{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"}],"person":[{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/"},{"id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/"},{"id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/"},{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/"},{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","route":"/people/hatem-soliman/"},{"id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","route":"/people/jeffrey-lancet/"},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/"},{"id":"patrick-hwu","kind":"person","name":"Patrick Hwu","route":"/people/patrick-hwu/"},{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/"},{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/"}],"journal":[{"id":"cancer-control","kind":"journal","name":"Cancer control","route":"/journals/cancer-control/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"institution":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/"}],"idea":[{"id":"idea-bio1-adaptive-therapy-platform","kind":"idea","name":"A multi-cancer platform trial of adaptive (dose-holiday) therapy","route":"/ideas/idea-bio1-adaptive-therapy-platform/"},{"id":"idea-moon-closed-loop-adaptive-therapy","kind":"idea","name":"Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models","route":"/ideas/idea-moon-closed-loop-adaptive-therapy/"},{"id":"idea-tr1-adaptive-therapy-randomised-phase-2","kind":"idea","name":"Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials","route":"/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/"},{"id":"idea-bio1-evolutionary-tumour-boards","kind":"idea","name":"Evolutionary tumour boards with a modeller in the room","route":"/ideas/idea-bio1-evolutionary-tumour-boards/"},{"id":"idea-bio1-first-strike-second-strike","kind":"idea","name":"Switch drugs at maximum response, not at relapse","route":"/ideas/idea-bio1-first-strike-second-strike/"}],"pathway":[{"id":"clonal-evolution","kind":"pathway","name":"Clonal evolution & minimal residual disease","route":"/pathways/clonal-evolution/"}],"paper":[{"id":"paper-c-144-01-lifileucel-melanoma-jco-2021","kind":"paper","name":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","route":"/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/"},{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/"},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/"}]}}